• Wed news: Lilly’s 4.5B medicine foundry project. 5 FDA decisions to watch in Q4. Hurricane Helene and the health supply chain. Lundbeck taps Charles River for AI-enabled neuro drug discovery. Amgen tax evasion lawsuit. See more on our front page

biologic

  1. Toxic Work Culture Forcing Loyal Employees to Flee

    Leadership we all know we’ve had people leave in all areas of biologics division at record numbers. Some said they weren’t leaving for better pay or promotion but dysfunction and toxic state within division led people who had been fully committed to Ilumya to leave. An even bigger red flag is...
  2. Salaries Please Explain Rationale

    Please will someone in leadership explain why current biologics applicants are being given higher range of base pay than first wave of hires back late 2018, Jan 2019? Is this an act of desperation to get people to join? Since salary discrepancies are widely known on Iluyma team (and...
  3. Bet...Biologics Dead Before They Start

    Let's see how long this "elite" group of reps hired to sell a NOT YET approved drug last. First, Tildra's data is OLD and pathetically bad compared to established bilologics already out and definitely bad compared to newer IL-23s coming. Ask your derm offices if they hear these new elite reps...